September 30, 2022The American Journal of GastroenterologyOpen Access

Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe

View Full Paper

Ask AI

Bookmark

Authors

FMFrançis MégraudUniversity of Helsinki DGDavid Y. GrahamUniversità Cattolica del Sacro Cuore CHColin W. HowdenUniversity of Tennessee at Knoxville

Abstract

The resistance rates observed in this study argue against the continued empiric use of proton pump inhibitor-based triple therapy containing clarithromycin, per treatment guidelines, and highlight the need for antibiotic resistance surveillance and novel treatment strategies for H. pylori infection in the US and Europe.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mégraud et al. (2022) studied this question.

synapsesocial.com/papers/69d7c9d23b601d7be3ae2f19 https://doi.org/10.14309/ajg.0000000000002045

View Full Paper

Ask AI

Bookmark

Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe

Abstract

Discussion

Cite This Study

Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe

Abstract

Discussion

Cite This Study

Also Consider

Also Consider